

# **Exhibit 56**

# Quarterly Compliance Report to Board of Directors 2Q2014

---


Bert Weinstein  
Vice President, Corporate Compliance  
August 14, 2014



U.S. - 45

# Compliance Summary for 2Q2014

---



Purdue continues to have strong systems and processes in place to prevent and detect violations of law, regulations and company policies, and to remediate issues before they become significant problems.

***No significant compliance issues in the 2<sup>nd</sup> quarter, or to date in 2014***

The following pages report on Purdue's Sunshine Act reporting and on Compliance audits during 2Q2014






# Sunshine Act

**PURDUE**

®

U.S. - 47

# 2014 Sunshine Act filing (2013 data)



- Sunshine filing timely made in June for six Purdue “Applicable Manufacturer” entities - - see below
- The “General Dollar” amount of \$3,774,933 will be the reported spend on the CMS website in September; “Research Dollars” will be reported on a delayed basis in the future to protect confidential R&D information

Applicable Manufacturer	General (# transactions)	Research (# Transactions)	Total Transactions	General Dollars	Research Dollars *	Total Dollars
Purdue Pharma L.P.	22,892	953	23,845	2,732,705.04	6,263,169.61	\$8,995,874.65
Rhodes Pharmaceuticals L.P.	1	13	14	87.56	646,708.70	\$646,796.26
Purdue Products L.P.	4	0	4	5,669.96	0	\$5,669.96
Purdue Neuroscience Company	0	77	77	0	361,266.46	\$361,266.46
Purdue Transdermal Technologies L.P.	2420	4	2424	1,036,125.59	9,349.54	\$1,045,475.13
Purdue Pharma of Puerto Rico	17	0	17	345.19	0	\$345.19
<b>TOTAL</b>	<b>25,334</b>	<b>1,047</b>	<b>26,381</b>	<b>3,774,933.34</b>	<b>7,280,494.31</b>	<b>\$11,055,427.65</b>



# “Dispute” period for HCPs/Teaching Hospitals

---



- During the period July 14<sup>th</sup> - August 27<sup>th</sup>, HCPs and Teaching Hospitals may view data and raise disputes with CMS as to spend reported by Applicable Manufacturers
- To date, no disputes have been received (perhaps, because, in order to dispute spend, recipients must first register on the CMS website, requiring personal data and a complicated process?)
- Corporate Compliance will manage any disputes with relevant business areas affected to preserve customer relations
- CMS plans to make all Applicable Manufacturers' data public September 30<sup>th</sup>



# Compliance Audits



U.S. - 50

# Compliance Audits Completed – 2Q2014



## Managed Care

- To provide a level of assurance that Purdue Managed Care Account Executives and Area Managers were performing activities in compliance to the Managed Care SOP.
- No Critical Findings; Findings concerning documentation of issues on FCRs, submission timing of FCRs, accuracy / timing of expense submissions, timing of call note entries, and call note reviews by managers. Remediation is underway

## Aggregate Spend - Commercial

- To verify that Sales Representatives were properly documenting expenses related to Health Care Professionals
- No Critical Findings; Findings concerning data and documentation accuracy and manager oversight. This was a follow up audit from 2013, to assure accurate state and federal spend reports.

The Purdue logo, featuring the word 'PURDUE' in a bold, sans-serif font, with a stylized oval shape to its right.

U.S. - 51



# Compliance Audits In Progress – 2Q2014



## Speaker Programs

- To assess compliance with speaker program procedures and company guidelines
- Report pending – preliminary findings include: size of speaker bureau may be too large for the number of programs; but significant improvements from 2011 Compliance audit

## Contracts with HCPs and payment at FMV

- To assess compliance with contracting and fair market value procedures
- Report pending - No Critical Findings; found a small percentage of transactions did not have a Statement of Work associated with the HCP's contract

# Questions?

---



If there are any questions or comments, please  
contact Bert Weinstein at  
[bert.weinstein@pharma.com](mailto:bert.weinstein@pharma.com), or at 203-588-8288



U.S. - 53